Eli Lilly change objectives results in the study of Alzheimer drugs ;
Eli Lilly, said Tuesday it has changed the objectives of results of a study late-stage patients of its experimental drug followed closely by Alzheimer’s disease, solanezumab.
The Expedition3 trial had two primary outcomes: changes in cognition of the participants and their daily function. Now cognition will remain a primary outcome measure, while the function is a secondary measure of efficacy of the drug.
Eli Lilly and Co., based in Indianapolis, said in a statement that made the change because “new scientific evidence supports the idea that cognitive decline precedes and predicts functional decline” in patients Alzheimer.
late-stage studies are usually the last before drug developers seeking regulatory approval.
Investors, apparently nervous about the news after some other drugs like Alzheimer’s drug manufacturers develop also failed the tests, leading shares down $ 2.67, or 3.6 percent, to $ 71.24.
Credit Suisse analyst Dr. VAMIL Divan wrote to investors that the news of the uncertainty about “what was already a high-risk program.” Adds
added that understands the reason for making the change now “why the study should ultimately be positive.” Divan wrote that he still sees a “path of the drug so it is on the market.”
If that happened, it would almost definitely solanezumab generate billions in annual sales. This is because existing Alzheimer’s drugs only temporarily alleviate symptoms, leaving doctors little to offer to help patients and their caregivers.
Solanuzumab works on cleaning of a substance called beta amyloid in the brain before it is grouped into plaques that are the hallmark of mental illness steal. It is being studied for the treatment of patients with early Alzheimer’s disease in the hope that it would prevent that damage.
About 5.3 million Americans, most of them over 65 years, has Alzheimer’s disease, which is the sixth leading cause of death in the US, according to the Alzheimer’s Association.
The number of Alzheimer’s patients worldwide is now estimated at 47 million and is expected to jump to almost 132 million in 2050.
This article was originally published on medicalxpress, Read the original article
Posted in: Alzheimer's disease & dementia